Brain Metastases of HER2-Positive Breast Cancer Patients Effectively Treated with Antibody ...
An antibody-drug conjugate, T-DXd, shows 'impressive' activity against HER2-positive breast cancer with brain metastases, according to the DESTINY-Breast 12 trial. Median progression-free survival was 17.3 months for patients with brain metastases, with 61.6% achieving 12-month PFS and 71% showing intracranial objective response. Side effects were consistent with previous studies, emphasizing the need for monitoring.
Reference News
An antibody-drug conjugate, T-DXd, shows 'impressive' activity against HER2-positive breast cancer with brain metastases, according to the DESTINY-Breast 12 trial. Median progression-free survival was 17.3 months for patients with brain metastases, with 61.6% achieving 12-month PFS and 71% showing intracranial objective response. Side effects were consistent with previous studies, emphasizing the need for monitoring.